2,346 reports of this reaction
2.0% of all DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED reports
#9 most reported adverse reaction
NASOPHARYNGITIS is the #9 most commonly reported adverse reaction for DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, manufactured by AAA Pharmaceutical, Inc.. There are 2,346 FDA adverse event reports linking DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED to NASOPHARYNGITIS. This represents approximately 2.0% of all 117,087 adverse event reports for this drug.
Patients taking DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED who experience nasopharyngitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NASOPHARYNGITIS is a less commonly reported adverse event for DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, but still significant enough to appear in the safety profile.
In addition to nasopharyngitis, the following adverse reactions have been reported for DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED:
The following drugs have also been linked to nasopharyngitis in FDA adverse event reports:
NASOPHARYNGITIS has been reported as an adverse event in 2,346 FDA reports for DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED. This does not prove causation, but indicates an association observed in post-market surveillance data.
NASOPHARYNGITIS accounts for approximately 2.0% of all adverse event reports for DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, making it a notable side effect.
If you experience nasopharyngitis while taking DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.